Loading
companiesCompany
Radiopharm Theranostics
Radiopharm Theranostics is an Australia-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the radiopharmaceuticals 161Tb-RAD402, 177Lu-BetaBart and the PET tracer RAD101 in prostate cancer, colorectal cancer, non-small-cell lung cancer and ovarian cancer.
Also called: Radiopharm Theranostics, Ltd
Overview
Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer, using nanobody, antibody, small-molecule and peptide platforms directed at targets other than PSMA, FAP and SSTR2. It has a joint venture with MD Anderson Cancer Center and is listed in Australia and on Nasdaq. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07189871 (phase 1/2, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Me...), NCT07259213 (phase 1/2, A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC) and NCT06777433 (phase 2, Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Melbourne, AU
Type
Radiopharmaceuticals · ASX:RAD, NASDAQ:RADX
Stage
Public
Website
Founded
2021
Similar pages
- TargetMUTYH
Shares Brain and spinal cord tumours (all types), Endometrial cancer, Ovarian cancer, Colorectal cancer.
- TargetDICER1
Shares Brain and spinal cord tumours (all types), Endometrial cancer, Ovarian cancer, Colorectal cancer.
- CompanyMedpace
Shares Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors.
- TargetRAD51D
Shares Brain and spinal cord tumours (all types), Ovarian cancer, Prostate cancer, Colorectal cancer.
- TargetDROSHA
Shares Brain and spinal cord tumours (all types), Ovarian cancer, Non-small-cell lung cancer.
- TrialA Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Shares Brain and spinal cord tumours (all types), Prostate cancer.
- TrialTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Shares Brain and spinal cord tumours (all types), Non-small-cell lung cancer.
- CompanyTYK Medicines
Shares Brain and spinal cord tumours (all types), Non-small-cell lung cancer.